Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 7/20 | 0.55 |
| ▸ | ESR1 | P03372 | 6/20 | 0.55 |
| ▸ | TTR | P02766 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ESRRB | O95718 | 1/20 | 0.41 |
| ▸ | ESRRA | P11474 | 1/20 | 0.41 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7794275 | 0.98 | ESR2 (0.53) | ESR2ESR1TTRCYP1A2ESRRB | |
| SCHEMBL622672 | 0.84 | ALDH1A1 (0.50) | ESR2ESR1TTRCYP1A2ESRRB | |
| SCHEMBL4468871 | 0.78 | PLAU (0.63) | ESR2ESR1 | |
| SCHEMBL1060994 | 0.77 | ESR2 (0.59) | ESR2ESR1TTRCYP1A2HSD17B14 | |
| SCHEMBL29522954 | 0.77 | ESR2 (0.59) | ESR2ESR1TTRCYP1A2HSD17B14 | |
| SCHEMBL29447040 | 0.77 | BACE1 (0.50) | PDE3BPDE3AALDH1A1 | |
| SCHEMBL198060 | 0.77 | BACE1 (0.50) | PDE3BPDE3AALDH1A1 | |
| Bromide SCHEMBL23412828 | 0.77 | PLAU (0.61) | ESR2ESR1 | |
| SCHEMBL16500490 | 0.76 | ESR1 (0.49) | ESR2ESR1TTRCYP1A2HSD17B14 | |
| SCHEMBL27671114 | 0.76 | ESR2 (0.57) | ESR2ESR1TTRCYP1A2HSD17B14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119285543-B | Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine | 南京工业大学 | 2026-05-15 | — | — | CN | claimed |
| CN-119285543-A | Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine | 南京工业大学 | 2025-01-10 | — | — | CN | claimed |
| CN-103200820-B | As the substd quinolines compound of GSNO reductase inhibitor | Nivalis Therapeutics (US) | 2016-04-06 | — | — | CN | claimed |
| CN-119285543-B | Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine | 南京工业大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260125410-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | UNIV YALE (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260083723-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | TORAY INDUSTRIES, INC. (JP) | 2026-03-26 | — | — | US | disclosed |
| US-12570639-B2 | Tetrahydroquinoline derivative and medicinal use thereof | TORAY INDUSTRIES, INC. (JP) | 2026-03-10 | — | — | US | disclosed |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | TERNS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250388614-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | UNIV YALE (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4658263-A2 | COMPOUNDS AND METHODS FOR TREATING, AMELIORATING, OR PREVENTING ARTHRITIS | Yale University (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | disclosed |
| CN-1628109-A | Novel aryl-and heteroaryl-piperazines | NOVO NORDISK AS (DK) | 2005-06-15 | — | — | CN | disclosed |
| WO-2005037285-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AS INHIBITORS OF RAF KINASE FOR TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050085482-A1 | 2,6-Disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of RAF kinase | CHIRON CORPORATION (US) | 2005-04-21 | — | — | US | disclosed |
| EP-1501801-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | UCB, S.A. (BE) | 2005-02-02 | — | — | EP | disclosed |
| EP-1474401-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2004-11-10 | — | — | EP | disclosed |
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC | 2003-12-25 | — | — | US | disclosed |
| WO-2003093237-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | UCB, S.A. (BE) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003093237-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | UCB, S.A. (BE) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003066604-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085482-A1 | 2,6-Disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of RAF kinase | RAF1, BRAF, ARAF | ESR2 3785/4885ESR1 4601/4885TTR 4864/4885 |
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HRH3, HRH2, HRH4 | ESR2 448/4885ESR1 703/4885TTR 4616/4885 |
| US-20260083723-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | AIFM2, GPX1, SOD1 | ESR2 860/4885ESR1 3396/4885TTR 3107/4885 |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | ASGR1, LDLR, FCGR2A | ESR2 1540/4885ESR1 2058/4885TTR 257/4885 |
| US-12570639-B2 | Tetrahydroquinoline derivative and medicinal use thereof | AIFM2, GPX1, GPX4 | ESR2 411/4885ESR1 3178/4885TTR 4477/4885 |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | ESR2 248/4885ESR1 1751/4885TTR 154/4885 |
| US-20260125410-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, COL2A1, FCGR2A | ESR2 219/4885ESR1 361/4885TTR 699/4885 |
| US-20250388614-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, COL2A1, LDLR | ESR2 335/4885ESR1 525/4885TTR 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.